Perran Fulden Yumuk

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Michael Boyer, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu et al. · Journal of Clinical Oncology · 2021 · 246 citations · Full text

HPV DNA frequency and subset analysis in human breast cancer patients' normal and tumoral tissue samples.

Mahmut Gümüş, Perran Fulden Yumuk, Taflan Salepçi et al. · PubMed · 2006 · 98 citations

Tumoral Tissue Samples, Viral Diagnostics, Immunology +16

Extrapulmonary Small Cell Carcinoma: Multimodality Treatment Results

Meriç Şengöz, Ufuk Abacıoğlu, Taflan Salepçi et al. · Tumori Journal · 2003 · 70 citations